Skip to main content
SpringerLink
Log in

In June 2012, the EMA's CHMP recommended that the marketing authorisation granted to Loraxin [loratadine] in Finland should not be recognised

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. EMA.Re-examination of arbitration procedure - Loraxin. Internet Document: [2 pages], 18 Oct 2012. Available from: URL: http://www.ema.europa.eu

Download references

Additional information

Key words

Pharmacovigilance; Loratadine; therapeutic use; Benefit-risk-assessment; adverse reactions; drug-induced; Various-toxicities; Urticaria; treatment; Allergic-rhinitis

Rights and permissions

Reprints and permissions

About this article

Cite this article

In June 2012, the EMA's CHMP recommended that the marketing authorisation granted to Loraxin [loratadine] in Finland should not be recognised. React. Wkly. 1426, 5 (2012). https://doi.org/10.2165/00128415-201214260-00013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214260-00013

Keywords

Search

Navigation